ALGORAE PHARMACEUTICALS LIMITED — Call Transcript 2015

Jun 17, 2015

==> picture [99 x 57] intentionally omitted <==

Living Cell Technologies Limited

ACN: 104 028 042 ASX: LCT OTCQX: LVCLY

ASX ANNOUNCEMENT

LCT hosts conference call on Clinical Study in Parkinson’s

• Conference call held with Living Cell Technologies senior management

• Shareholders spoke live to CEO, Dr Ken Taylor and Principal Investigator, Dr Barry Snow

• Living Cell Technologies advancing regenerative cell therapy into larger Phase IIb study to evaluate its potential as a disease-modifying treatment

18 June 2015 – Sydney, Australia, and Auckland, New Zealand – Living Cell Technologies Limited (LCT) has released a recording of a conference call held today, Thursday 18 June 2015 at 8.30am AEST / 10.30am NZST.

Investors and interested parties who were unable to join the call are welcome to access the call via the links below.

On the call, LCT’s Chief Executive Officer, Dr Ken Taylor and Principal Investigator, Dr Barry Snow, discussed the company’s recently announced clinical trial results. The Phase I/IIa study investigated NTCELL[®] an experimental regenerative cell therapy being studied as a disease-modifying agent in Parkinson’s disease, with safety as a primary endpoint. The study showed that NTCELL[® ] implantation was well-tolerated with no adverse events or serious adverse events considered to be related to NTCELL[®] .

NTCELL[®] implantation was also shown to improve clinical features of Parkinson’s disease in the four patients studied, as measured by validated neurological rating scales and questionnaires, with the improvement sustained at 26 weeks post-implant. The first patient treated continued to show improvement in neurological scores at 74 weeks post-implantation.

LCT plans to initiate a Phase IIb study in the fourth quarter of 2015. The study will be led by Dr Snow at Auckland City Hospital. The efficacy and safety endpoints will be the same as those evaluated in the Phase I/IIa study.

Dr. Taylor and Dr. Snow also answered a number of questions relating to LCT’s planned subsequent Phase IIb trial.

A recording of the call can be accessed here: http://www.openbriefing.com/OB/1811.aspx and will also be available on the LCT website: www.lctglobal.com

ENDS

About NTCELL

NTCELL, a unique cell therapy, is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells that are sourced from a unique herd of designated pathogen-free pigs bred from stock originally discovered in the remote sub-Antarctic Auckland Islands. Choroid plexus cells are naturally occurring “support” cells for the brain and secrete CSF, which contains a range of factors that support nerve cell functions and protective enzymes that are crucial for nerve growth and healthy functioning. In NTCELL, the porcine choroid plexus cells are coated with LCT’s propriety technology IMMUPEL™ to protect them from attack by the immune system. Therefore, no immunosuppressive regimen is required for treatment.

Following implantation into a damaged site within the brain, NTCELL functions as a neurochemical factory producing CSF and secreting multiple nerve growth factors that promote new central nervous system (CNS) growth and repair disease-induced nerve degeneration while potentially removing waste products such as amyloids and proteins.

NTCELL has the potential to treat neurodegenerative diseases because choroid plexus cells help produce CSF as well as a range of neurotrophins (nerve growth factors) that have been shown to protect against neuron (nerve) cell death in animal models of disease. NTCELL has been shown in preclinical studies to regenerate damaged tissue and restore function in animal models of Parkinson’s disease, stroke, Huntington’s disease, hearing loss and other non-neurological conditions, such as wound healing. In addition to Parkinson’s disease, NTCELL has the potential to be used in a number of other CNS indications, including Huntington’s, Alzheimer’s and motor neurone diseases including amyotrophic lateral sclerosis (ALS).

About Parkinson’s disease

Parkinson’s disease is a progressive neurological condition characterised by a loss of brain cells that produce dopamine (a neurotransmitter that conveys messages between brain cells to ensure effective movement and planning of movement) and many other types of neurons. People with Parkinson’s disease experience reduced and slow movement (hypokinesia and bradykinesia), rigidity and tremors.

Parkinson’s disease is the second most common neurodegenerative disorder after Alzheimer’s disease, affecting approximately 4 million people worldwide. The average age of onset is 60 years, and the incidence increases with age. Men are one and a half times more likely to have Parkinson's disease than women.

Current treatments for Parkinson’s disease are symptomatic and do not reverse or slow the degeneration of neurons in the brain. Most existing pharmaceutical treatment options focus on restoring the balance of dopamine and other neurotransmitters. The effectiveness of dopamine replacement therapy declines as the disease progresses. When dopamine treatments are no longer useful, some patients are treated with Deep Brain Stimulation (DBS), in which a medical device is surgically implanted in the brain in order to send electrical impulses to regions of the brain involved in the control of movement. While DBS leads to short-term symptomatic improvement, it does not impact disease progression and is not curative or neuroprotective.

About Living Cell Technologies

Living Cell Technologies (LCT) is an Australasian biotechnology company improving the wellbeing of people with serious diseases worldwide by discovering, developing and commercialising regenerative treatments that restore function using naturally occurring cells. LCT’s unique proprietary encapsulation delivery technology, IMMUPEL™, coats cells with protective capsules that prevent them from attack by the immune system. This allows cell therapies to be used without the need for immunosuppressive drugs. LCT’s lead product, NTCELL[®] , is being developed for neurodegenerative diseases. LCT recently completed a Phase I/IIa clinical trial of NTCELL in New Zealand for the treatment of Parkinson’s disease and plans to initiate a Phase IIb study in the fourth quarter of 2015. LCT holds a 50 percent interest in Diatranz Otsuka Limited, which is developing DIABECELL[®] , a cell therapy in late-stage clinical trials for the treatment of type 1 diabetes. LCT is listed on the Australian (ASX: LCT) and United States (OTCQX: LVCLY) stock exchanges. The company is incorporated in Australia, with research and development and operations based in New Zealand. For more information, visit www.lctglobal.com or follow @lctglobal on Twitter.

Forward-looking statement

This document contains certain forward-looking statements, relating to LCT’s business, which can be identified by the use of forward-looking terminology such as “promising,” “plans,” “anticipated,” “will,” “project,” “believe,”

“forecast,” “expected,” “estimated,” “targeting,” “aiming,” “set to,” “potential,” “seeking to,” “goal,” “could provide,” “intends,” “is being developed,” “could be,” “on track,” or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA’s and other health authorities’ requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management’s expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

# #

Media Contacts: United States New Zealand Australia Carolyn Wang Rachael Joel Catie Corcoran BrewLife Botica Butler Raudon Partners Buchan WE Tel: +1 415 946 1065 Tel: +64 9 303 3862 Tel: +61 2 9237 2807 Mobile: +1 415 225 5050 Mobile: +64 21 403 504 Mobile: +61 422 045 536 cwang@brewlife.com rachaelj@botica.co.nz ccorcoran@buchanwe.com.au